| 教員紹介トップページへ | 三重大学トップページへ |
| 職名 | 寄附講座教授 | |||||||||
| 氏名 | やまぐち もとこ 山口 素子 |
|||||||||
| 生年月 | ||||||||||
|
||||||||||
| TEL | 059-231-9072 | |||||||||
| FAX | 059-231-9113 | |||||||||
| myamaguchi@clin.medic. (末尾に mie-u.ac.jp を補ってください) | ||||||||||
| 個人のホームページ | https://www.hosp.mie-u.ac.jp/lymphoma/ | |||||||||
| 学歴 | 三重大学医学部 学士課程 (～1989年)
|
|||||||||
| 学位 | 1997.12 医学博士 三重大学
|
|||||||||
| 所属学会 | 日本内科学会 (総合内科専門医、指導医) 日本血液学会 (認定専門医、指導医、代議員、診療委員-医薬品等承認・供給、造血器腫瘍診療ガイドライン委員会委員、女性活躍委員会委員、学術・統計調査委員) 日本リンパ網内系学会 (理事、評議員、診療保険委員会委員長) 日本癌学会 (評議員) 日本臨床腫瘍学会 日本癌治療学会 米国血液学会 米国臨床腫瘍学会 | |||||||||
| 社会活動 | WHO分類(2008) リンパ系腫瘍 臨床諮問委員会(CAC) 委員
JCOG (日本臨床腫瘍研究グループ) 効果・安全性評価委員会 副委員長、難治性リンパ腫小班 代表 造血器腫瘍取扱い規約第1版 分担執筆担当 一般社団法人グループ・ネクサス・ジャパン (悪性リンパ腫全国患者会) 顧問 UpToDate(TM) Topic co-author |
|||||||||
| 職歴 | 1989. 6. 三重大学医学部附属病院第二内科研修医 1990. 1. 市立伊勢総合病院内科研修医 1991. 4. 国立療養所明星病院内科医員 1993. 1. 三重大学医学部第二内科医員 2002. 10. 三重大学医学部第二内科助手 2007. 4. 三重大学医学部附属病院血液内科講師 2020. 11. 三重大学大学院医学系研究科血液・腫瘍内科学准教授 2021．4．三重大学大学院医学系研究科先進血液腫瘍学講座教授 | |||||||||
| 学術（芸術）賞 | 三医会賞(2018) | |||||||||
| 専門分野 | 悪性リンパ腫 | |||||||||
| 現在の研究課題 | 悪性リンパ腫の病態解明と新規治療法の開発 | |||||||||
| 担当科目 | 血液内科学
悪性リンパ腫 |
|||||||||
| 主な業績等 | Shimada K, Yamaguchi M, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol 21: 593-602, 2020
Sawaki A, Miyazaki K, Yamaguchi M, et al. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy. Int J Hematol 111: 686-91, 2020 Miyazaki K, .., Yamaguchi M. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study. Haematologica 105: 2308-15, 2020 Yamaguchi M, et al. Improved prognosis of extranodal NK/T-cell lymphoma, nasal type of nasal origin but not extranasal origin. Ann Hematol 98: 1647-55, 2019 Yamaguchi M, Suzuki R. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-9. Extranodal NK/T-cell lymphoma, nasal type (ENKL). Int J Hematol 109: 371-6, 2019 (Guidelines) Yamaguchi M, Oguchi M, Suzuki R. Extranodal NK/T-cell lymphoma: updates in biology and management strategies. Best Pract Res Clin Haematol 31: 315-21, 2018 (Review) Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood 131: 2528-40, 2018 (Review) Takeuchi T, Yamaguchi M, et al. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Cancer 123: 1166-73, 2017 Yamaguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan. J Clin Oncol 35: 32-9, 2017 Kobayashi K, Yamaguchi M, et al. Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B-cell lymphoma cells and their association with clinical features. Cancer Med 5: 1802-9, 2016 Yamaguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 30:4044-6, 2012 (Correspondence) Suzuki R, Yamaguchi M, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 118:6018-22, 2011 Yamaguchi M, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29: 4410-6, 2011 Miyazaki K, Yamaguchi M, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol 22: 1601-7, 2011 Yamaguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 27: 5594–600, 2009 Miyazaki K, Yamaguchi M, et al. Gene expression profiling of peripheral T-cell lymphoma including gamma/delta T-cell lymphoma. Blood 113:1071-4, 2009 Yamaguchi M, et al. De novo CD5+ diffuse large B-cell lymphoma: Results of a detailed clinicopathological review in 120 patients. Haematologica 93:1195-202, 2008 Miyazaki K, Yamaguchi M, et al. Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression. Br J Haematol 142:562-70, 2008 Yamaguchi M, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016-20, 2008 Kimura M, Yamaguchi M, et al. Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma. Int J Hematol 85:41-8, 2007 Murase T, Yamaguchi M, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109: 478-85, 2007. Ueno S, Yamaguchi M, et al. Expression of CD29 on lymphoma cells and/or CD36 on microvascular endothels correlates with high serum LDH level in diffuse large B-cell lymphomas (DLBCLs) and is frequent in de novo CD5-positive DLBCLs. Int J Oncol 27:1241-6, 2005 Ogawa S, Yamaguchi M, et al. CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. Br J Haematol 125:180-6, 2004 Kobayashi T, Yamaguchi M, et al. Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5- diffuse large B-cell lymphomas. Cancer Res 63:60-6, 2003 Yamaguchi M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815-21, 2002 Yamaguchi M, et al. Treatment outcome of nasal NK-cell lymphoma: A report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematopathol 41:93-9, 2001 Yamaguchi M, et al. Successful autologous peripheral blood stem cell transplantation for relapsed intravascular lymphomatosis. Bone Marrow Transplant 27:89-91, 2001 Yamaguchi M, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 105: 1133-9, 1999 Yamaguchi M, et al. gamma/delta T-cell lymphoma: a clinicopathologic study of 6 cases including extrahepatosplenic type. Int J Hematol 69: 186-95, 1999 Yamaguchi M, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76: 2351-6, 1995 Yamaguchi M, et al. Discordant reaction of Leu4 and rabbit anti-human CD3-epsilon in sinonasal ‘T’-cell lymphoma. Int J Hematol 59: 25-30, 1993 |
|||||||||